在接受PCI的缺血性心脏病患者中,单抗,双抗和三抗血小板治疗之间的比较,网络元分析
Ali Saad Al-Shammari1, Ahmed Ibrahim2, Laila Shalabi3
1College of Medicine, University of Baghdad, Baghdad, Iraq.
Current problems in cardiology
|July 30, 2024
概括
双重和三重抗血小板治疗与单一治疗相比,在接受PCI的缺血性心脏病患者中增加出血风险. 在心脏死亡,心脏病发作,支架血栓形成或中风方面没有发现显著差异.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 干预心脏病学 干预心脏病学
背景情况:
- 缺血性心脏病 (IHD) 的管理往往涉及皮肤冠状动脉干预 (PCI).
- 抗血小板治疗在PCI后至关重要,以预防血栓事件.
- 最佳的抗血小板策略 (单,双或三重) 仍然是积极研究的领域.
研究的目的:
- 为了比较单 (SAPT),双 (DAPT) 和三 (TAPT) 抗血小板方法的疗效和安全性.
- 评估包括心脏死亡,心肌梗塞 (MI),支架血栓,中风和严重出血 (BARC 3-5) 在接受PCI的IHD患者中的结果.
主要方法:
- 通过使用到2024年4月1日的数据进行了网络元分析.
- 包括25项研究,共65115名患者.
- 在R研究中使用netmeta包分析了主要结果.
主要成果:
- 在SAPT,DAPT和TAPT之间没有观察到心脏死亡,心脏病发作,支架血栓形成或中风的显著差异.
- 与SAPT相比,DAPT和TAPT都显示出严重出血的风险增加 (BARC 3-5).
- 与SAPT相比,DAPT显示大出血风险在统计学上显著增加.
结论:
- 双 (DAPT) 和三 (TAPT) 抗血小板疗法与单一 (SAPT) 治疗相比,患出血事件的风险更高.
- 目前的证据不支持SAPT,DAPT和TAPT之间缺血事件率 (心脏死亡,心肌梗塞,支架血栓,中风) 的显著差异.
相关概念视频
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
505
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
505
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
481
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
481
01:18Cardiovascular Drugs: Classification based on Therapeutic Indications
2.2K
Cardiovascular diseases, encompassing a range of conditions, can significantly affect the heart's operations and the overall circulatory system. These conditions impair the heart's ability to pump blood, leading to a deficit in oxygen supply to crucial organs. Anomalies in the heart's electrical system, known as arrhythmias, can cause heartbeats to accelerate or slow down. Usually, heart rates increase during physical activity and decrease while resting or sleeping. However,...
2.2K
01:16Antianginal Drugs: Nitrates and β-Blockers
564
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
564
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
165
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
165
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
152
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
152